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Summary.We have determined lupus anticoagulants, anti-b2
glycoprotein I (b2GPI) and antiprothrombin antibodies in
the Leiden Thrombophilia Study, a population-based case–
control study designed to determine risk factors for deep
venous thrombosis (DVT). Lupus anticoagulant (LAC) was
measured in 473 patients and 472 control subjects. Four
control subjects (0.9%) and 14 patients (3.1%) had a
positive LAC, resulting in a 3.6-fold increased risk [odds
ratio (OR) 3.6, 95% CI: 1.2–10.9]. Of the total population,
49 were positive for anti-b2GPI antibodies: 15 controls
(3.4%) and 34 patients (7.5%), implying a 2.4-fold increased
risk (95% CI: 1.3–4.2). Antiprothrombin antibodies were
present in 114 subjects: 48 controls (11.0%) and 66 cases
(14.6%) with an OR of 1.4 (95% CI: 1.0–2.1). When LAC
was considered in the co-presence of antiprothrombin or
anti-b2GPI antibodies the OR increased to 10.1 (95% CI:
1.3–79.8). A LAC without a positive anti-b2GPI or antipro-
thrombin test was not associated with a risk for DVT (OR
1.3, 95% CI: 0.3–6.0). This study demonstrates that the
presence of LAC, anti-b2GPI antibodies and antiprothrom-
bin antibodies are risk factors for DVT in a general
population. The strongest association holds for the combi-
nation LAC and the presence of anti-b2GPI or antipro-
thrombin antibodies.
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Introduction
Deep venous thrombosis is a common disease in the Western
society with an incidence of one to two per 1000 inhabitants per
year [1]. The pathogenesis of venous thrombosis is complex,
and it has become increasingly clear that deregulation of
coagulation is amain cause of deep venous thrombosis. A large
number of genetic risk factors related to unbalance of
hemostasis have been recognized and in at least 60% of the
patients one of these genetic risk factors can be found [2].
Besides genetic factors, acquired risk factors, such as immobil-
ization, female hormone use and malignancies play a major
role. The presence of antiphospholipid antibodies is considered
as an important acquired risk factor that disturbs normal
hemostasis [3]. The association between the presence of
antiphospholipid antibodies and thrombosis has been ﬁrmly
established for patients with autoimmune diseases such as
Systemic Lupus Erythematosus [4].
The presence of anti-phospholipid antibodies (aPL) in
plasma can be detected by either a prolongation of phosphol-
ipid-dependent coagulation tests (lupus anticoagulants, LAC),
or by solid-phase immunoassays [5]. Meta-analyses performed
on all the published studies showed that the predictive value of
assays that measure LAC activity correlate much better with a
history of thrombosis than the presence of anticardiolipin
antibodies. Different types of antibodies can cause LAC, both
anti-b2-glycoprotein I (b2GPI)- and antiprothrombin antibod-
ies have been shown to prolong coagulation in vitro [6,7]. The
predictive value of ELISAs speciﬁc for autoantibodies directed
against b2GPI or prothrombin is unclear [8].
The incidence of LAC in the general population and its effect
on the risk of thrombosis is not well established. The studies
published included only small patient cohorts [9–11]. In the
present study, we investigated the presence of LAC, anti-
b2GPI- and antiprothrombin antibodies in the Leiden Throm-
bophilia Study (LETS), a large population-based case–control
study of unselected patients with a ﬁrst venous thrombosis,
designed to estimate the contribution of genetic and acquired
risk factors to venous thrombosis.
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Patients and methods
Patients
The LETS is a population based case–control study designed
to determine risk factors for deep venous thrombosis [12]. The
study includes 473 patients and 472 controls. The methods by
which blood samples were obtained and interview data were
collected have been described elsewhere [12]. The Leiden
ethics committee approved the study protocol, and all
participants gave their informed consent. Brieﬂy, consecu-
tively diagnosed patients younger than 70 years of age who
had a ﬁrst objectively conﬁrmed episode of deep venous
thrombosis between January 1988 and December 1993 and
who had no known malignancy were selected through three
anticoagulation clinics in the Netherlands. These clinics
monitor anticoagulant treatment for all outpatients in well-
deﬁned geographic areas. All thrombi were proximal, 452
patients suffered from thrombosis in the leg and 21 patients
suffered from thrombosis in the arm. Controls, who were
either acquaintances or partners (225, 47%) of patients in the
study, were frequency matched for age (within 5 years) and
sex.
Samples
Blood was collected in tubes containing 0.106 mol L)1 triso-
dium citrate. Plasma was prepared by centrifugation at 2000 g
for 10 min at room temperature and stored at )70C in
suitable aliquots. Samples were obtained at least 6 months after
the thrombotic event and at least 3 months after discontinu-
ation of oral anticoagulant treatment, however, 48 patients
were still using oral anticoagulants at the time of drawing of
blood because of early recurrences or arterial indications.
Plasma samples used for the measurement of LAC activity had
not been thawed before, whereas detection of anti-b2GPI- and
antiprothrombin antibodies was performed on samples that
had been thawed and re-frozen once. As during the collection
of the plasma samples the blood was centrifuged once while the
recommendation for LAC testing is double centrifugation, we
have tested with known LAC positive and negative samples
whether this procedure was adequate to measure LAC. The
results of these tests showed that the centrifugation procedure
was sufﬁcient to measure LAC.
Assays
For all laboratory tests, the technician was unaware of whether
the blood sample was from a patient or a control, and results
were unblinded only after all results were entered into a
database. LAC was measured with a dilute Russell’s Viper
Venom Time (dRVVT, Gradipore, Australia). Because of the
limited amount of samples, the screening assay for LAC as
recommended was bypassed and LAC testing was directly
performed on samples diluted 1:1 with pooled normal plasma.
A sample was considered positive when the clotting time was
longer than the mean of 40 healthy controls + 3 SD (LAC
screen). For those samples that showed a prolonged clotting
time, a conﬁrmation assay was performed with added phosp-
holipids (LAC conﬁrm). If addition of extra phospholipids
resulted in a clotting time reduction of more than 20%, the
sample was considered LAC positive [LAC ratio: LAC screen
(1:1)/LAC conﬁrm (1:1) >1.2].
The presence of anti-b2GPI IgG and IgM antibodies was
measured as described before [13]. A positive patient sample
was used for calibration and the results of this sample were
arbitrarily set at 100 arbitrary units (AU). A sample was
considered positive when the optical density (OD) for IgG or
IgM measurement was higher than the OD of the mean of 40
controls + 3 SD (6.2 AU).
The presence of antiprothrombin IgG and IgM antibodies
was measured as described before [13]. A positive patient
sample was used for calibration and the results of this sample
were arbitrarily set at 100 AU. A sample was considered
positive when the OD for IgG or IgMmeasurement was higher
than the OD of the mean of 40 controls + 3 SD (14.75 AU).
Other assays
The activated protein C (APC) activity was measured as
described previously in an activated partial thromboplastin
time (APTT)-based assay [14]. APTT was measured using
Cephotest (Nycomed, Oslo, Norway). C-reactive protein was
measured with a sandwich-enzyme immunoassay as described
previously [15].
Statistics
As an estimator of the risk in those with abnormalities
relative to those without, we calculated odds ratios (OR) with
accompanying 95% CI, according to Woolf [16]. ORs were
also calculated for various cut-off points for continuous
variables, which were based on percentiles of the distribution
in the control population. Adjustment for age, sex and other
co-variates was performed by unconditional logistic regres-
sion.
Results
The mean age of the patients and controls at the time
of thrombosis was 45 years (range patients 15–69, controls
15–79). Fifty-nine percent of cases and controls were women
(Table 1).
Lupus anticoagulants
Of the total population, 18 persons were positive for LAC. Of
these, 13 (72.2%)were women. Themean age of those with and
without LAC was similar (45.0 and 43.0 years, respectively).
Among the 472 control subjects, four persons were positive
(0.9%), whereas 14 of the 473 patients with thrombosis were
positive (3.1%). This implies a 3.6-fold increased risk for deep
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venous thrombosis for individuals positive for LAC relative to
those negative for LAC (OR 3.6, 95% CI: 1.2–10.9; Table 2).
When patients (n ¼ 48, of whom three were patients with
positive LAC) on oral anticoagulants were excluded from the
analysis, the OR decreased slightly (OR 3.1, 95% CI: 1.0–9.8).
We tested the inﬂuence of LAC on APC-sensitivity in an
APTT-based assay. When restricted to those subjects that were
not using anticoagulants, the APC-ratio was similar in patients
with a positive LAC (APC ratio 0.85, 95% CI: 0.77–0.93) and
patients without LAC (APC ratio 0.88, 95% CI: 0.86–0.90).
To determine whether the predictive value of the LAC assay
would increase by varying the cut-off levels, the LAC ratios
were set at 1.1, 1.2, 1.3 and 1.4. Elevated risks were found for all
cut-off values, without a graded dose–response. The a priori
deﬁned cut-off at a ratio of 1.2, which is used routinely in our
center, gave the highest OR (Table 3).
Anti-b2GPI-antibodies
Of the total study population, 49 individuals had positive
results for anti-b2GPI antibodies: 15 controls (3.4%) and 34
cases (7.5%). This implies a 2.4-fold increased risk for deep
venous thrombosis associated with having anti-b2GPI anti-
bodies (OR 2.4, 95% CI: 1.3–4.2; Table 2). This OR was
determined for a cut-off level set a priori at the mean + 3 SD
of 40 healthy controls (6.2 AU). When the cut-off level was set
at the 70th (3.6 AU), 80th (4.1 AU), 90th (4.9 AU), or 95th
percentile (5.8 AU) of the control population of our study,
there was an increasing OR for increasing cut-off points, with a
1.9-fold increased risk (95% CI: 1.1–3.2) at antibody titers
exceeding the 95th percentile (Table 4).
Antiprothrombin antibodies
Of the total population, 114 were positive for antiprothrombin
antibodies: 48 controls (11.0%) and 66 cases (14.6%), leading
to a mildly elevated risk (OR 1.4, 95% CI: 1.0–2.1; Table 2).
This OR was determined with a cut-off level of the
mean + 3 SD (14.75 AU) of 40 controls, as routinely used.
When the cut-off level was set at the 70th (10.4 AU), 80th (12.0
AU), 90th (14.9 AU) or 95th percentile (19.3 AU) of the
control population in this study, the ORs were 1.3–1.4 for all
cut-off values applied (Table 5).
Combinations of abnormal tests
Of the 18 individuals with LAC, ﬁve were positive for
antiprothrombin antibodies and anti-bGPI antibodies, two
had only antiprothrombin antibodies, four only anti-bGPI
antibodies, and seven had neither antiprothrombin nor anti-
bGPI antibodies. Interestingly, three of the four control
subjects with LAC had neither antiprothrombin nor anti-
bGPI antibodies (as compared with three of 14 patients).When
we only considered LAC in the co-presence of either antipro-
thrombin or anti-bGPI antibodies (10 of 473 patients and one
of 472 controls), the risk of thrombosis associated with a LAC
becamemuch higher, with a 10-fold increased risk (OR ¼ 10.1,
Table 2 Odds ratios (OR) and 95% CI for thrombosis for antiphosp-
holipid antibodies
Assay OR (95% CI)
Lupus anticoagulants 3.6 (1.2–10.9)
Anti-b2-Glycoprotein antibodies 2.4 (1.3–4.2)
Antiprothrombin antibodies 1.4 (1.0–2.1)
Table 3 Inﬂuence of LAC cut-oﬀ levels on the risk for thrombosis.
OR (odds ratio), 95% CI
Cut-oﬀ
(LAC ratio)
No. of
patients
No. of
controls
OR
(95% CI)
>1.1 38 23 1.9 (1.1–3.3)
>1.2 14 4 3.6 (1.2–10.9)
>1.3 7 3 2.4 (0.6–9.1)
>1.4 6 2 3.0 (0.6–15.1)
Table 4 Inﬂuence of anti-b2GPI antibody cut-oﬀ level on the risk for
thrombosis
Cut-oﬀ (percentile) No. of patient No. no controls OR (95% CI)
P70 159 141 1.2 (0.9–1.6)
P80 104 94 1.1 (0.8–1.6)
P90 63 49 1.3 (0.9–2.0)
P95 42 23 1.9 (1.1–3.2)
Mean + 3 SD 34 15 2.4 (1.3–4.2)
Table 5 Inﬂuence of antiprothrombin antibody cut-oﬀ level on the risk for
thrombosis
Cut-oﬀ (percentile) No. of patient No. of controls OR (95% CI)
P70 175 141 1.4 (1.0–1.8)
P80 119 96 1.3 (1.0–1.8)
P90 64 47 1.4 (0.9–2.1)
P95 32 23 1.4 (0.8–2.4)
Mean + 3 SD 66 48 1.4 (1.0–2.1)
Table 1 Characterization of all patients and control subjects
LAC negative
(ratio <1.2)
LAC positive
(ratio >1.2)
Men (number) 399 5
Women (number) 531 13
Age (mean) 44.9 43.4
APTT (s, mean) 27.8 34.9
CRP (mg L)1, mean) 3.1 10.0
Anti b2-glycoprotein
I antibody positive
42 7
Anti b2-glycoprotein
I antibody negative
886 11
Antiprothrombin antibodies positive 105 9
Antiprothrombin antibodies negative 821 9
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95% CI: 1.3–79.8). A LAC without antibodies to either
prothrombin or bGPI, present in four patients and three
controls, did not affected risk (OR 1.3, 95% CI: 0.3 to 6.0).
Discussion
We have studied the risk of deep venous thrombosis associated
with antiphospholipid antibodies in a population-based
case–control study bymeasuringLAC, prothrombin antibodies
and anti-b2GPI-antibodies. LAC is present in 1%of the control
population and 3.1% of the patients, and its presence increased
the risk of thrombosis 3.6-fold. Anti-b2GPI-antibodies were
found in 3.4% of the population and 7.5% of the patients and
increased the risk of thrombosis 2.4-fold, whereas antipro-
thrombin antibodies were detectable in 11% of the population
and 14.6% of the patients, resulting in a relative risk of 1.4.
WhenLACwas considered in combinationwith a positive anti-
b2GPI or antiprothrombin ELISA, the risk increased to 10.1. A
LAC without positive ELISAs did not affect the risk. These
ﬁndings demonstrate that antiphospholipid antibodies are
present in a distinct incidence in the general population, and
have a signiﬁcant effect on the occurrence of thrombosis.
Several studies have demonstrated that LAC is a strong risk
factor for thrombosis in patients with autoimmune disease [4].
We conﬁrm this observation in a population who were
otherwise apparently healthy. In an attempt to increase the
predictive value for thrombotic complications, we analyzed the
risk of combinations of assays. When besides LAC also anti-
b2GPI or antiprothrombin antibodies were present, the risk
increased a further three times. This indicates that a combined
screening for LAC and anti-b2GPI and antiprothrombin
antibodies will improve the diagnosis of the antiphospholipid
syndrome. The percentage of patients positive for LACwas too
low to analyze the contribution of anti-b2GPI antibodies and
antiprothrombin antibodies separately.
The incidence of LAC in patients with SLE and thrombosis
is very high (40–60%) [17–19] and one of our aims was to assess
the incidence of LAC in individuals without an underlying
systemic autoimmune disease. In a study with 65 unselected
patients, Ginsberg et al. [9] found nine patients positive for
LAC (14%). In another study with 59 unselected patients with
DVT, Simioni et al. [10] found ﬁve LAC positive patients
(8.5%). Apparently, in unselected patients with thrombosis as
in our study, the incidence of LAC is much lower than in
patients with autoimmune disease.
We have found 4 positive LAC patients in a cohort of 436
controls (0.9%). Ginsberg et al. [9] found three positive samples
in a total of 179 patients referred for suspected venous
thrombosis who turned out not to have venous thrombosis
(1.7%), while Simioni et al. [10] did not ﬁnd any positive LAC
in their control cohort of 117 persons (0%). In an older study
Nencini et al. [10] studied 55 healthy volunteers and found only
one LAC positive person (1.8%). These data seem to agree well
on a incidence of LAC in the general population around 1%.
One of the major problems in diagnosing patients with the
antiphospholipid syndrome is the decision whether a serolog-
ical markers is positive or negative. It is not known above
which level antiphospholipid antibodies should be considered
as pathological. In this study, we have compared different
cut-off levels for LAC, anti-b2GPI and antiprothrombin
antibodies. In our original publication [13], we used a ratio
between dRVVT without extra phospholipids and with extra
phospholipids of 1.2. Our current study demonstrates that
this was a good choice, as this ratio had the highest
association with DVT. It is not known if the same ratio is
also the optimal cut-off level for arterial thrombotic compli-
cations. For anti-b2GPI antibodies a cut-off level of the mean
of 40 controls + 3 SD also appeared a satisfactory cut-off
value. For antiprothrombin antibodies the choice of the cut-
off level did not inﬂuence the association, which, although
present, was much weaker than for the other so-called
antiphospholipid antibodies.
It has been suggested that the presence of LAC leads to
APC-resistance [20]. In the present study we did not ﬁnd an
effect of the presence of LAC on the APC-resistance, indicating
that the increased risk for deep venous thrombosis found in
patients with LAC was not because of an inﬂuence on protein
C pathway.
Autoimmunity is more often seen in women than men. In
accordance to this, about 80% of the patients with the
antiphospholipid syndrome are women. In the cohort studied
here, the majority of LAC-positive samples were from women
(72%), and the sex distribution was not different between cases
and controls.
Individuals with a positive LAChave higher levels of CRP in
their blood compared with individuals without LAC. Blood
was collected at least 6 months after the thrombotic event. It is
difﬁcult to imagine how infections would speciﬁcally raise LAC
in patients who had suffered thrombosis so long ago. However,
we could not exclude that a positive LAC because it is often
related to autoimmune disease, leads to an inﬂammatory
response and an increased CRP.
In conclusion, the presence of antiphospholipid antibodies is
a risk factor for venous thrombosis of the deep leg veins in
patients without a known underlying autoimmune disease. A
combination of LAC with anti-b2GPI or antiprothrombin
antibodies confers the highest risk for deep venous thrombosis.
Although the incidence of LAC in unselected patients with
DVT is much lower than in patients with systemic autoimmune
disease, around 1% of the population has a detectable
abnormality increasing the risk of thrombosis.
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